NCT03716856: Phase 1 - CAR-BCMA T in Patients With Refractory or Relapsed Multiple - Chinese study
NCT03502577: Phase 1 - BCMA-Specific CAR T-Cells Combined With Gamma Secretase Inhibitor (JSMD194)
NCT03773107: Phase 1/2: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib RRMM
IMF - International Myeloma Foundation: Patient Handbook
IMF - International Myeloma Foundation: Understanding Freelite and Hevylite Tests
IMF - International Myeloma Foundation: Understanding Fatigue
NCT03715478: Phase 1/2: Multi-Center Study of GSK2857916 With Pomalidomide & Dex - Algonquin trial
FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 + Dexamethasone (Kd70) in relapsed Myeloma
NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
NCT03673826: Phase 2: Carfilzomib, Lenalidomide and Dex Versus Lenalidomide and Dex High- Risk SMM
NCT03539744: Phase 3 - A Study of Venetoclax/Dex Compared With Pomalidomide/Dex - t(11;14) +ive RRMM
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
NCT03448978: Phase 1/2 - Descartes-08 - anti-BCMA-CAR-mRNA-trans. auto CD8+ T cells in Myeloma
NCT03556332: Phase 2 - Carfilzomib, Lenalidomide, Dex Daratumumab for relap. MM with auto transplant
FDA Approved for NDMM Transp. Ineligible: Daratumumab + Bortezomib (Velcade), Melphalan, Prednisone
Medicosis Perfectionalis : Electrophoresis, Immunoelectrophoresis and Immunofixation
FDA authorizes ClonoSEQ assay, a next generation sequencing (NGS) test for minimal residual disease
NCT01554852: Phase 3- Thalidomide, Lenalidomide, Carfilzomib, Bortezomib, Vorinostat-NDMM Myeloma XI
NCT03767257: Phase 2: A Study of Colesevelam for Lenalidomide-Associated Diarrhea
NCT03756896: Phase 2: Carfilzomib, Pomalidomide, and Dexamethasone in High-Risk Myeloma
NCT03617731: Phase 3 - Effect of Isatuximab to RVd Induction and Len Maintenance in NDMM (GMMG HD7)
NCT03544281: Phase 2: GSK2857916 /Len/Dex Vs GSK2857916/Bortezomib/Dex - RRMM Myeloma - DREAMM 6
NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT03464916: Phase 1: Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in RRMM